Two separate studies were made of the tuberculin reactivity of lepromatous and tuberculoid patients and of normal population controls to the same stock and dose of PPD (0.0001 mg. or 5 TU). In the first study, the age-adjusted frequencies of tuberculin reactions were: for lepromatous patients 58.1%, for tuberculoid patients 82.2% and for healthy controls 86.7%. In the second study the corresponding figures were: 47.4% for the lepromatous, 61.2% for the tuberculoid and 81.3% for the healthy controls. In addition, only 35.0% of the lepromatous patients gave strong reactions of ++ and +++ intensity as compared to 48.7% of such reactions in the control populationA definite lowering of frequency of tuberculin reactivity has thus been established in patients with lepromatous leprosy, although about 50% were still found to react to 5 TU PPD. It appears from our findings that a reduction in frequency of tuberculin reactivity likewise occurs in tuberculoid patients during reactional phases in which they become bacteriologically positive. (Summary)
Tuberculin

A blood tuberculin test is described based on the hypothesis that a high degree of tuberculin hypersensitiveness could be widespread even to the nucleated cellular elements of the blood. The reactions produced by the challenging drop of PPD tuberculin inside the hypersensitive cells have been fairly demonstrated. The test appears to be specific for human mycobacterium tuberculosis. The Editors of the Journal hope to stimulate, through publication of this article, similar studies by other investigators in this field
Tuberculin Test, Blood, Tuberculin

Tuberculin ; Philippines

Tuberculin Test

The relative sensitivity of tuberculin testing was studied with the use of a commercial preparation of Vollmers Patch, Mantoux 0.1 mg. OT, and first strength dose (0.00002 mg.) Purified Protein Derivative, and 1.0 mg. OTIt was found that the Vollmers Patch is almost as sensitive as Mantoux 0.1 mg. and better than first strength dose of PPD, but about 16.6% less sensitive than 1.0 mg. OTIn spite of some minor objections, the patch test is the method of choice to be recommended in the first testing for tuberculin reaction. It should be followed by either 1 mg. OT, or 0.002 (1/2 second strength dose) of PPD. (Summary and Conclusion)
Tuberculin Test

Comparative tuberculin tests were made on 6,140 children of four groups: National Chest Center, Tondo (slum area) Elementary School, the Elementary Department of the Philippine Normal College (public school), and the San Francisco Elementary School(rural area), using Moro patch with State Serum Institute tuberculin jelly, and Mantoux (Intradermal), using PPD tuberculin solution of 1 and 10 Tuberculin Units. Results were as follows: 1. Moro and Mantoux (1 T.U.) tests correlated fairly well up to seven years in the NCC and Tondo groups, and up to 15 years in the two other groups2. Mantoux 10 T.U. was superior to the Moro patch in all groups at all ages , except for the first 2 years, where there was very close correlation3. Moro tests are far inferior to the Mantoux 10 T.U. in eliciting hypersensitivity, following BCG vaccination4. The use of the tuberculin patch is desirable only as a screening test, but should be followed by Mantoux tests of higher dosage than 1 T.U., when results with the Moro are negative5. A limited series of Moro tests using State Serum Institute jelly and jelly prepared by Allan and Hanburys, England, showed the SSI jelly to be more potent and satisfactory for routine use. (Summary and conclusions)
Tuberculin Test, Child, Vaccination, Tuberculin

We conducted tuberculin test with tuberculin 2UI 0,1ml PPD 23 Tween 80 by Copenhagen among 250 children who had BCG immunization after 3 months. The results of study: the positive rate of tuberculin test was 62%, 51.2% diameter of positive reaction was 6-10 mm. The positive rate of tuberculin test among the children who had breast feeding was higher among the rest group children (65.8% vs. 51.5%). Age of children when injection (during the first three months), weight of birth, a way of delivery did not influence to the positive rate of tuberculin test.
Tuberculin ; Child ; Mycobacterium bovis

No abstract available.
Tuberculin Test ; Tuberculosis*

Background: Verruca vulgaris ranked 10th in the top 10 diseases in 2019 seen among the Philippine Dermatological Society training institutions. The efficacy of immunotherapy, such as intralesional zinc sulfate (ZS), for warts were reported. Considering the limited studies with promising results on verruca, a study on the efficacy and safety of intralesional zinc in the treatment of verruca was considered. Objective: This study aims to determine the efficacy and safety of intralesional 2% ZS in comparison to intralesional purified protein derivative (PPD) among adult patients with verruca vulgaris. Methods: This is a double-blind, randomized, controlled trial involving 44 patients allocated to group ZS (n=22) and PPD (n=22). Intralesional injections of ZS or PPD to the largest wart were done at weeks 0, 2, 4, 6, 8, 10. Clearance and size reduction of the target and distant wart at 12th week and recurrence at 14th week were assessed. Adverse effects were checked. Results: At the 12th week of treatment, higher proportion in group ZS patients achieved total resolution of the target lesion compared to PPD, but results were not statistically significant (29% vs. 19%). Both groups showed decline in the target lesion size. The median size reduction between the two groups showed no significant differences. Three patients from group ZS showed clearance of distant warts while none in group PPD. There was no recurrence of all previously resolved warts. Adverse reactions were pain, edema, and erythema. Conclusion Intralesional 2% zinc sulfate (29%) was efficacious and safe compared to Intralesional PPD (19%) but the difference was not statistically significant. There was clearance of distant warts in 5% of group ZS patients. The mild adverse events did not warrant discontinuation of treatment.
Zinc Sulfate ; Tuberculin

Introduction: Intralesional purified protein derivative (PPD) is an affordable therapeutic option that has been studied for cutaneous warts. However, the lack of good evidence precludes its widespread use. Objective: To determine the efficacy and safety of intralesional PPD in the treatment of cutaneous warts. Methods: A systematic search for controlled clinical trials comparing intralesional PPD and placebo or any conventional therapy was conducted using electronic databases. The included studies were assessed for risk of bias, and data such as clearance rate of target and distant lesions, recurrence rate, and adverse events were extracted. Analysis was done through RevMan v5.3. Results: Four controlled clinical trials composed of 205 patients were included. All of the studies compared intralesional PPD to placebo as comparator. Intralesional PPD had a significantly higher clearance rate of target wart (RR=0.43[0.22,0.84], P=0.01) and a significantly higher clearance rate of distant lesions (RR=0.59[0.41,0.85], P=0.005) as compared to placebo. However, there was no significant difference in the recurrence rate (RR=0 [-0.07,0.07], P=0.98). Adverse events reported were only considered minor. Conclusion Intralesional PPD is an effective and safe treatment option for cutaneous warts. However, more well-structured RCTs with longer follow-up period and those comparing it with conventional treatment are needed to further support its use.
Warts ; Meta-Analysis ; Tuberculin